Metsera reported encouraging Phase I results for its amylin analogue MET-233i, exhibiting dose-dependent weight loss and a pharmacokinetic profile supporting once-monthly dosing. This therapy may offer a differentiated mechanism alongside GLP-1 drugs, fueling optimism about its potential as a durable obesity treatment option.